healthneutral
Semaglutide: A Potential Shield Against Dementia?
Case Western Reserve University, USATuesday, June 24, 2025
The study highlights semaglutide as a promising candidate for dementia prevention. However, it only shows a correlation, not a definitive cause-and-effect relationship. Encouraging as the findings are, more research is needed. Novo Nordisk, the company behind Ozempic and Wegovy, is already conducting large-scale trials to test semaglutide’s effectiveness against Alzheimer’s. The results of these trials, expected this year, could provide clearer answers.
In the meantime, the research team plans to investigate other GLP-1 drugs, like tirzepatide, to see if they offer even greater protection against dementia. While the current findings are promising, they should be viewed with caution. Dementia is complex, and while semaglutide might play a role in prevention, it’s not a guaranteed solution.
Actions
flag content